Physician decision making in anticoagulating atrial fibrillation: a prospective survey of a physician notification system for atrial fibrillation detected on cardiac implantable electronic devices of patients at increased risk of stroke

被引:0
|
作者
Cloutier, Justin M. [2 ,3 ]
Khoo, Clarence [2 ,3 ]
Hiebert, Brett [2 ]
Wassef, Anthony [4 ]
Seifer, Colette M. [1 ,2 ]
机构
[1] Univ Manitoba, Sect Cardiol, WRHA Cardiac Sci Program, Winnipeg, MB R2H 2A6, Canada
[2] St Boniface Gen Hosp, Cardiac Sci Program, Y3019, Winnipeg, MB R2H 2A6, Canada
[3] Univ Manitoba, Sect Cardiol, Winnipeg, MB, Canada
[4] Univ Toronto, Div Cardiol, Toronto, ON, Canada
关键词
anticoagulation; atrial fibrillation; devices; subclinical;
D O I
10.1177/1753944717749739
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The objectives of this study were to evaluate the effectiveness of a physician notification system for atrial fibrillation (AF) detected on cardiac devices, and to assess predictors of anticoagulation in patients with device-detected AF. Methods: In 2013, a physician notification system for AF detected on a patient's CIED [including pacemakers, implantable cardioverter defibrillators (ICD) or cardiac resynchronization therapy (CRT) devices] was implemented, with a recommendation to consider oral anticoagulation in high-risk patients. We prospectively investigated the effectiveness of this system, and evaluated both patient and physician predictors of anticoagulation, as well as factors influencing physician decision making in prescribing anticoagulation. Both uni- and multivariable analysis as well as descriptive statistics were used in the analysis. Results: We identified 177 patients with device-detected AF, 126 with a CHADS(2) >= 2. Only 41% were prescribed anticoagulation at any point within 12 months. On multivariable analysis, stroke risk as predicted by CHADS(2) was not a predictor of anticoagulation. ASA use predicted a lower rate of anticoagulation (OR 0.39, 95% CI 0.16-0.97, p = 0.04); physicians in practice for <20 years were more likely to prescribe anticoagulation (OR 3.39, 95% CI 1.28-8.93, p = 0.01); and physicians who believed both cardiologist and family doctor should be involved in managing anticoagulation were more likely to prescribe anticoagulation (OR 3.28, 95% CI 1.02-10.5, p = 0.05). Conclusions: Patients on aspirin were less likely to be anticoagulated. Physicians in practice for <20 years and who believed that both the general practitioner and cardiologist should be involved in managing anticoagulants were more likely to prescribe anticoagulation.
引用
收藏
页码:113 / 122
页数:10
相关论文
共 50 条
  • [21] Impact of atrial fibrillation ablation on activity minutes in patients with cardiac implantable electronic devices
    Peigh, Graham
    Stanelle, Evan
    Ziegler, Paul D.
    Varberg, Nathan
    Soderlund, Dana
    Passman, Rod S.
    HEART RHYTHM, 2022, 19 (09) : 1405 - 1411
  • [22] Association of Atrial Fibrillation Burden and Mortality Among Patients With Cardiac Implantable Electronic Devices
    Peigh, Graham
    Zhou, Jiani
    Rosemas, Sarah C.
    Roberts, Anthony I.
    Longacre, Colleen
    Trinh, Katherine
    Nayak, Tanvi
    Soderlund, Dana
    Passman, Rod S.
    CIRCULATION, 2024, 150 (05) : 350 - 361
  • [23] Digoxin and increased risk of stroke in patients with atrial fibrillation
    Mackall, JA
    Laurita, KR
    HEART RHYTHM, 2005, 2 (05) : 530 - 531
  • [24] Erratum to: Noise from a dysfunctional atrial lead detected as atrial fibrillation by a cardiac implantable electronic device
    S. S. Barold
    F. Van Heuverswyn
    Herzschrittmachertherapie + Elektrophysiologie, 2017, 28 (1) : 63 - 63
  • [25] Serotonin antidepressants and atrial fibrillation burden from cardiac implantable electronic devices
    Koh, Youlin
    Kwok, Cecilia
    Voskoboinik, Aleksandr
    Kalman, Jonathan M.
    Wong, Michael
    JOURNAL OF ARRHYTHMIA, 2023, : 876 - 883
  • [26] Predictors of Atrial Fibrillation Free Survival in Patients With Implantable Cardiac Devices
    Mai, Phu
    Kim, Michael H.
    Roka, Attila
    CIRCULATION, 2022, 146
  • [27] Atrial Fibrillation Burden Reduction From Antiarrhythmic Drugs in Patients With Cardiac Implantable Electronic Devices
    Schwartz, Sarah M.
    Peigh, Graham
    Culler, Kasen
    Mathew, Daniel
    Verma, Rhea
    Lemma, Betelehem
    Passman, Rod S.
    CIRCULATION, 2023, 148
  • [28] Tactics of anticoagulant therapy in patients with cardiac implantable electronic devices and subclinical atrial fibrillation: A review
    V. Razina, Tatiana
    V. Serova, Maria
    Andreev, Denis A.
    Sazonova, Yulia S.
    Komarova, Anna G.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (04) : 353 - 359
  • [29] Atrial fibrillation and remote monitoring through cardiac implantable electronic devices in heart failure patients
    Boriani, Giuseppe
    Imberti, Jacopo F.
    Vitolo, Marco
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (03) : 554 - 556
  • [30] Association of atrial fibrillation burden with rhythm control and stroke prevention interventions among patients with cardiac implantable electronic devices
    Peigh, G.
    Zhou, J.
    Roberts, A. I.
    Rosemas, S. C.
    Longacre, C.
    Schwab, G.
    Soderlund, D.
    Passman, R. S.
    EUROPEAN HEART JOURNAL, 2023, 44